NCT06457789

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Amsterdam UMC, location VUmc · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor. This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	[18F]F-AraG PET imaging	Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.
DRUG	[89Zr]Zr-Df-Crefmirlimab PET imaging	Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.

Timeline

• Start date: 2024-12-01
• Primary completion: 2027-08-01
• Completion: 2028-07-01
• First posted: 2024-06-13
• Last updated: 2025-04-02

Locations

1 site across 1 country: Netherlands